Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

A7986

Atovaquone

≥98% (HPLC), powder, anti-protozoal agent

Synonym(s):

Mepron, trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
10 mg
Please contact Customer Service for Availability
$116.00
50 mg
Please contact Customer Service for Availability
$431.00

About This Item

Empirical Formula (Hill Notation):
C22H19ClO3
CAS Number:
95233-18-4
Molecular Weight:
366.84
MDL number:
MFCD00889188
UNSPSC Code:
12352200
PubChem Substance ID:
329770944
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

$116.00

Please contact Customer Service for Availability
​
Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Atovaquone, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

storage temp.

−20°C

SMILES string

OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O

InChI

1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-

InChI key

KUCQYCKVKVOKAY-CTYIDZIISA-N

Application

Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.

Biochem/physiol Actions

Atovaquone in an anti-protozoal mitochondrial electron transport inhibitor. It also functions as an antimalarial and antipneumocystic agent.
Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML1662SML1804A7232
Atovaquone ≥98% (HPLC)

Sigma-Aldrich

A7986

Atovaquone

Buparvaquone ≥98% (HPLC)

Sigma-Aldrich

SML1662

Buparvaquone

AM4113 ≥98% (HPLC)

Sigma-Aldrich

SML1804

AM4113

AP-18 ≥98% (HPLC), solid

Sigma-Aldrich

A7232

AP-18

form

powder

form

powder

form

powder

form

solid

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

200

Quality Level

100

Quality Level

100

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >10 mg/mL

solubility

DMSO: soluble, chloroform: soluble

solubility

DMSO: 2 mg/mL, clear (warmed)

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

originator

-

originator

-

originator

-

Still not finding the right product?

Explore all of our products under Atovaquone

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000531318
0000531318
0000519780
0000519762
0000519762

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Steven Gabardi et al.
Clinical transplantation, 26(3), E184-E190 (2012-04-11)
Pneumocystis pneumonia (PCP) is associated with significant morbidity and mortality in renal transplant recipients (RTR). Trimethoprim-sulfamethoxazole (TMP-SMZ) is considered the prophylactic agent-of-choice. Some patients require an alternative owing to TMP-SMZ intolerance. This is the first evaluation of full-dose atovaquone vs.
Kai J Rogers et al.
Cell reports, 30(12), 4041-4051 (2020-03-27)
During the 2013-2016 Ebola virus (EBOV) epidemic, a significant number of patients admitted to Ebola treatment units were co-infected with Plasmodium falciparum, a predominant agent of malaria. However, there is no consensus on how malaria impacts EBOV infection. The effect
Nehal Gupta et al.
Pharmaceuticals (Basel, Switzerland), 14(6) (2021-06-03)
Triple-negative breast cancer (TNBC) is considered to be the most aggressive and malignant neoplasm and is highly metastatic in nature. In the current study, we investigated the anti-metastatic potential of atovaquone, a protozoal drug prescribed for Pneumocystis pneumonia. We showed
View All Related Papers

Global Trade Item Number

SKUGTIN
A7986-10MG04061833390894
A7986-50MG04061833390900

Questions

Reviews

No rating value

Active Filters